By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Genmab is a Copenhagen-based cancer drug developer best known for its antibody technology platforms, DuoBody and HexaBody, and multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company is the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis) and has several pipeline candidates targeting other oncologic indications and autoimmune diseases.

Contact Information

Website: www.genmab.com
Email: r.gravesen@genmab.com
Main Phone: +45 70202728
Address: Kalvebod Brygge 43
City / Town: Copenhagen V
Country: DK
Postal Code: 1560

Issuer Information

Exchange: NGS
CEO: Jan G. J. van de Winkel
Employees: 781

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A